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Abnormal accumulation of protein inclusions in motor neurons has been known as a
major pathological change in amyotrophic lateral sclerosis (ALS). Increasing numbers of
proteins including mutant Cu, Zn-superoxide dismutase (SOD1) have been identified as
constituents of pathological inclusions in a form of insoluble fibrillar aggregates. Notably,
protein fibrillar aggregates exhibit a self-perpetuating property, which can convert a soluble
native protein into insoluble fibrillar aggregates. Such “seeding reaction” of protein
fibrils can accelerate the aggregation significantly and would contribute to the spread of
inclusion pathologies from an affected cell to its neighboring cells in neurodegenerative
diseases. In ALS, a pathological change first occurs at the site of disease onset and then
propagates throughout the affected tissues in a time-dependent manner; therefore, it can
be assumed that seeded aggregation may be the key factor of disease progression in
ALS. In this mini review, we will briefly summarize recent studies on possible roles of a
seeded aggregation of SOD1 in pathomechanism of ALS.
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INTRODUCTION
Many proteins gain physiological functions by folding into their
own unique three-dimensional structures, and any disturbance
during this folding process potentially disrupts protein functions,
which is considered to cause a variety of diseases (Morimoto,
2008). Among those, neurodegenerative diseases have been well
characterized by abnormal accumulation of “mis”-folded proteins
in brains and spinal cords of patients (Soto, 2003; Ross and
Poirier, 2004). More specifically, certain misfolded proteins form
insoluble, fibrillar aggregates that are rich in β-sheet structures,
widely known as amyloid (Nelson et al., 2005).
In many neurodegenerative diseases, neurological symptoms
appear in middle age (50 years ∼), suggesting that it is a
rare event for proteins to become misfolded/aggregated. In
fact, protein fibrillar aggregation in vitro requires a significant
conformational conversion of proteins to form oligomers (also
known as “nucleus”), which is a rate-limiting step of the overall
aggregation reaction (Harper and Lansbury, 1997). Once the
nucleus forms, however, it functions as a structural template
(or so called “seed”) to convert native proteins into β-sheet-
rich structures and then elongate the protein fibril. This mech-
anism, which accelerates and even triggers protein aggregation,
is called the seeding reaction. While it remains controversial
whether protein aggregation is the direct cause or a mere result
of neurodegeneration (Winklhofer et al., 2008; Treusch et al.,
2009), this seeding mechanism may explain why many neu-
rodegenerative diseases progress rapidly after the symptoms first
appear.
One notable example for a seeding reaction is the infectivity
of Prion diseases, in which the spread of fibrillar aggregates
of prion proteins is considered to be the main cause of neu-
rodegeneration (Prusiner, 1982; Aguzzi and Rajendran, 2009).
Fibrils of prion proteins are considered to work as infectious
agents that can be transmitted between individuals. As exem-
plified in kuru (Gibbs et al., 1980), eating affected tissues of
the disease could introduce fibrillar prion aggregates into a
brain of a healthy control as seeds and thereby trigger fibrilla-
tion of prion proteins and cause neurodegeneration. While no
infectivity between individuals has been reported in neurode-
generative diseases besides prion diseases so far, a seeding phe-
nomenon appears to be common to protein fibrillar aggregates
(Dobson, 1999); therefore, increasing numbers of researchers
have pursued possible roles of seeding reactions in patholo-
gies of neurodegenerative diseases (Aguzzi and Rajendran, 2009;
Polymenidou and Cleveland, 2011; Soto, 2012). For example,
Alzheimer’s disease (AD) is characterized by fibrillar aggregation
of Aβ peptides in brains (Hardy and Selkoe, 2002), and acceler-
ated accumulation of Aβ fibrils has been confirmed in primate
and rodent models that are injected with brain homogenates
of an AD patient (Meyer-Luehmann et al., 2006; Ridley et al.,
2006). Several other pathogenic proteins also forms fibrillar
aggregates in vitro, which have been tested for their in vivo
seeding activity by being transduced into cultured cells and
brains of transgenic mouse model (Aguzzi and Rajendran, 2009;
Polymenidou and Cleveland, 2011; Soto, 2012). A seeding reac-
tion of protein fibrils is thus considered to play important
roles in pathological progression of neurodegenerative diseases,
and in this mini review, we will focus upon roles of seeded
aggregation of proteins in pathologies of amyotrophic lateral
sclerosis (ALS).
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A SEEDED FIBRILLATION OF SUPEROXIDE DISMUTASE
(SOD1) AS A PATHOLOGICAL PROPAGATION OF
AMYOTROPHIC LATERAL SCLEROSIS (ALS)
ALS is a devastating motor neuron disease, mainly caused by
abnormal accumulation of inclusions in the spinal cord (Bruijn
et al., 2004). Notably, ALS has been known to occur as a
focal process, which spreads contiguously throughout upper and
lower motor neurons (Ravits and La Spada, 2009; Holmes and
Diamond, 2012; Kanouchi et al., 2012). In other words, motor
neuron degeneration in ALS is an orderly and actively propagating
process, which appears to share characteristics of a seeded aggre-
gation of proteins seen in Prion diseases.
Most ALS cases (∼90%) are sporadic with no known genetic
factors (sporadic ALS, sALS), while the remaining cases have been
known to exhibit a family history (familial ALS, fALS; Robberecht
and Philips, 2013). In 1993, dominant mutations in the gene
encoding Cu, Zn-superoxide dismutase (SOD1) were identified
as one of major genetic causes of fALS (Rosen et al., 1993),
and mutant SOD1 proteins have been known to accumulate
abnormally in the form of insoluble inclusions within affected
spinal motor neurons of SOD1-related fALS patients (Bruijn et al.,
1998). Ultrastructural analysis of SOD1-positive inclusions in
fALS cases has identified their fibrillar morphologies (Kato et al.,
2000); however, those inclusions were not stained by amyloid-
diagnostic dye, Thioflavin S, which has made it controversial
whether fibrillar aggregates of mutant SOD1 in vivo are rich in β-
sheets (Kerman et al., 2010). Moreover, SOD1-positive inclusions
have never been isolated from fALS cases, so further biochem-
ical tests will be required to characterize pathological SOD1
aggregates.
In contrast, SOD1-positive inclusions with ALS-like symp-
toms were reproduced in a fALS-model mouse expressing human
SOD1 with a pathogenic mutation (Turner and Talbot, 2008)
and were found to be stained by Thioflavin S, supporting the
formation of amyloid-like, β-sheet-rich fibrils in mouse (Wang
et al., 2002; Furukawa et al., 2008). Insoluble SOD1 aggregates
were also successfully isolated from the spinal cords of affected
fALS-model mice, and quite notably, those SOD1 aggregates
exhibited seeding activity toward fibrillation of purified SOD1
proteins in vitro. Chia et al. have prepared homogenates of
spinal cords of transgenic mice expressing human SOD1 with
G93A mutation and shown that the homogenates triggered fib-
rillation of wild-type as well as G93A-mutant human SOD1
proteins under in vitro conditions with acidic pH of solution
in the presence of a chaotropic reagent, guanidine hydrochlo-
ride (Chia et al., 2010). While destabilization of SOD1 pro-
teins under artificial conditions appears to be required for a
seeded acceleration of fibrillar aggregation, inclusions containing
mutant SOD1 would function as seeds and thereby contribute
to propagation of pathological changes among contiguous motor
neurons and then disease progression of SOD1-related fALS
cases.
Fibrillogenic propensities of SOD1 proteins have been well
characterized in in vitro studies using purified recombinant pro-
teins. SOD1 is a cytoplasmic enzyme (Chang et al., 1988) that cat-
alyzes the conversion of superoxide radicals to hydrogen peroxide
and oxygen (McCord and Fridovich, 1969) and is activated by
binding of a catalytic copper and a structural zinc ion and also
by forming an intramolecular disulfide bond (Furukawa et al.,
2004). Wild-type holo-SOD1 with a disulfide bond exhibits high
thermostability (Tm ∼ 90◦C), conferring significant resistance
to structural changes and aggregation (Forman and Fridovich,
1973). In contrast, when SOD1 lacks both metal ions and a disul-
fide bond (apo-SOD1SH), its melting temperature decreases down
to 43◦C and become more prone to misfolding and aggregation at
physiological temperature (Furukawa and O’Halloran, 2005). In
vitro aggregates of human SOD1 polypeptide without any modi-
fications possess amyloid-like characters with fibrillar morpholo-
gies and show a seeding activity to accelerate fibrillation of native
human SOD1 proteins (Furukawa et al., 2008). More importantly,
amyloid-like fibrils of human apo-SOD1SH retain their seeding
activity in the intracellular environment; transduction of those
human SOD1 fibrils into cultured cells (mouse neuroblastoma,
Neuro2a) has been shown to trigger the aggregation of stably-
transfected human SOD1 (Furukawa et al., 2013).
fALS-causing mutations have been shown to decrease affinity
for copper/zinc ions and/or stability of a disulfide bond (Hayward
et al., 2002; Tiwari and Hayward, 2003; Furukawa et al.,
2008). Therefore, in a reducing environment of the cyto-
plasm with high metal-chelating capacity, pathogenic mutations
are supposed to increase intracellular fractions of fibrillation-
prone apo-SOD1SH (Furukawa et al., 2008). Nonetheless, it
remains unclear how mutant SOD1 forms aggregates under
pathological conditions. To elucidate how SOD1 aggregates
form, several pathways for aggregation have been proposed in
SOD1 proteins in vitro (Furukawa, 2012b). As reported by
Munch et al. mutant SOD1 was found to form fibrillo-granular
aggregates by addition of trifluoroethanol (TFE; Münch and
Bertolotti, 2010), which penetrated inside neuronal cells through
macropinocytosis and then acted as seeds to trigger intracellular
aggregation of endogenously expressed SOD1 variants (Münch
et al., 2011). Once SOD1 aggregation occurs in a cell, the aggre-
gates can be released to the extracellular space and then trans-
ferred from cell to cell (vide infra). Intracellular aggregation of
mutant SOD1 is thus considered to be persistent and heritable
after passages, supporting prion-like propagation of aggregation
phenotypes.
As mentioned above, two distinct types of SOD1 aggregates,
i.e., apo-SOD1SH amyloids and TFE-induced aggregates, have
been found to function as seeds to trigger SOD1 aggregation
intracellularly, but their structural and biochemical properties
depend on how aggregation was induced (Furukawa et al., 2008;
Münch and Bertolotti, 2010). Based upon previous in vitro stud-
ies, several distinct pathways for aggregation are possible in SOD1
(Toichi et al., 2013) and are expected to produce SOD1 aggregates
with a varying degree of a seeding activity. This might describe
heterologous progression and severity of diseases among SOD1-
related fALS patients. Indeed, disease phenotypes of fALS cases
have been known to be variable among different mutations in
SOD1 (Wang et al., 2008), and furthermore, mutation-dependent
structures of SOD1 fibrils closely correlate with their distinct
biochemical properties (Furukawa et al., 2010). Therefore, it will
be interesting to test if SOD1 fibrils with different mutations
exhibit distinct activity as seeds in vitro and in vivo.
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PROPAGATION OF PROTEIN MISFOLDING IN AMYOTROPHIC
LATERAL SCLEROSIS (ALS)
In a seeding reaction, sheared pieces of insoluble fibrils can act
as structural templates for a “phase-like transition” from soluble
native conformers to generally insoluble fibrillar state, but this
view now appears to be necessary for revision. Grad et al. utilized
antibodies (3H1 and 10C12) that exclusively recognize misfolded
SOD1 with disease-specific epitopes, which are not available in the
natively folded state, and showed that misfolding of endogenous
wild-type SOD1 in human cells (e.g., human embryonic kidney
293 cells (HEK293)) is induced by co-expression of a soluble
misfolded form of human SOD1 with pathogenic mutations
(Grad et al., 2011). In other words, soluble misfolded conformers
of SOD1 are also transmissible without adopting classical, insolu-
ble fibrillar states. Furthermore, transient expression of mutant
human SOD1 in murine cells (e.g., Neuro2a) did not induce
misfolding of endogenous mouse wild-type SOD1 (Grad et al.,
2011). The difference lies in the amino acid sequence of murine
and human SOD1, where the only tryptophan in human SOD1
(Trp32) is replaced by serine in murine counterpart. Indeed,
misfolding of wild-type human SOD1 was observed by human
SOD1 with a pathogenic (G127X) mutation but was significantly
mitigated when G127X human SOD1 with W32S mutation was
used (Grad et al., 2011). Trp32 in human SOD1 is highly solvent-
exposed and distant from the native dimer interface, which might
provide an alternative site for abnormal intermolecular interac-
tions through hydrophobic interactions. It is interesting to note
that expression of mutant TAR DNA binding protein 43 (TDP-
43) and Fused in Sarcoma (FUS), pathogenic proteins also known
to be found in ALS patients (Arai et al., 2006; Neumann et al.,
2006; Kwiatkowski et al., 2009; Vance et al., 2009), can increase
the immunoreactivity for misfolded SOD1 using a disease-specific
antibody (3H1), both in patients and cultured human cells (SH-
SY5Y; Pokrishevsky et al., 2012). While pathological involvement
of wild-type SOD1 in ALS remains to be established, aberrant
conformers of wild-type SOD1 have been reported in sporadic
ALS with no genetic background (Furukawa, 2012a). Accordingly,
toxic conformers of SOD1 might be produced by abnormal inter-
actions of folded SOD1 with misfolded SOD1 or other proteins
(such as TDP-43/FUS) at the site surrounding Trp32. In other
words, as proposed in the template-assisted misfolding of prion
proteins (Horwich and Weissman, 1997), soluble but misfolded
conformers of protein molecules can be propagated through
abnormal interactions among homologous proteins even without
the formation of classical amyloid-like fibrils.
A CELL-TO-CELL TRANSFER OF INTRACELLULAR
SUPEROXIDE DISMUTASE (SOD1)
SOD1 is known as one of major intracellular proteins, and
most of SOD1 (∼70%) exist in the cytoplasm (Chang et al.,
1988). To confirm that seeded aggregation or misfolding of SOD1
is the key molecular mechanism of pathological propagation
of SOD1-fALS, it is required to understand how intracellular
misfolded/aggregated SOD1 is transferred from the cytoplasm
to extracellular environment. As a relatively simple process,
misfolded/aggregated SOD1 would be released to extracellular
environment by death of an affected cell and then phagocytosed
by the other cell. Recent studies have nonetheless suggested more
sophisticated processes for a cell-to-cell transfer of SOD1 proteins
(Grad et al., 2011; Münch et al., 2011). In fact, active secretion of
SOD1 to extracellular space has been suggested in several different
types of cultured cells (Mondola et al., 1996, 1998), and both wild-
type and mutant SOD1 can be also detected in the cerebrospinal
fluid of healthy controls as well as fALS patients (Zetterström
et al., 2011).
In conditioned media of mouse motor neuron-like hybrid
(NSC-34) cell line, impaired secretion of mutant SOD1 was
associated with intracellular formation of inclusions and toxicity,
suggesting secretion of mutant SOD1 as a beneficial process for
cell survival (Turner et al., 2005). In contrast, Urushitani et al.
have found that mutant SOD1 proteins are secreted in association
with chromogranins and cause microgliosis and neuron death
(Urushitani et al., 2006), leading to the idea that suppression
of extracellular mutant SOD1 is a promising strategy for ther-
apeutics of SOD1-related fALS cases. Indeed, passive as well
as active immunizations targeting extracellular mutant SOD1
proteins have successfully prolonged lifespan of transgenic mice
expressing mutant human SOD1 (Urushitani et al., 2007). Toxic
roles of secreted SOD1 are further supported by the findings
that motor neurons are killed by being co-cultured with astro-
cytes derived from adult neural progenitor cells isolated from
post-mortem lumber spinal cord tissues from sporadic ALS as
well as SOD1-related fALS (Haidet-Phillips et al., 2011). Also
importantly, suppression of SOD1 in both fALS and sporadic ALS
astrocytes was found to negate such toxicity of astrocytes toward
motor neurons. Recently, furthermore, Basso et al. have shown
the increased release of exosomes from astrocytes overexpressing
fALS-causing mutant SOD1 and found that astrocyte-derived
exosomes contained mutant SOD1 proteins and were transferred
to the cytoplasm of spinal neurons (Basso et al., 2013).
Based upon these results, secretion of SOD1 is considered
to occur through several distinct pathways and appears to be a
normal physiological process. Experimental evidences are further
required to show that secretory vesicles act as a messenger to gen-
erate seeding activity of SOD1. More specifically, conformational
analysis of SOD1 (folded, misfolded, or fibrillized) included in
those vesicles will reveal the molecular mechanism of pathological
propagation in ALS through a seeding reaction.
SUMMARY
As briefly summarized above, increasing numbers of recent stud-
ies have supported the idea that misfolding/aggregation of mutant
SOD1 is transmissible through a seeding mechanism inside the
cell and among cells. In that sense, it is interesting to test patho-
logical roles, if any, of SOD3, which resides at the extracellular
matrix and possesses a structural domain almost homologous to
SOD1 (Folz and Crapo, 1994). A SOD1-like domain of SOD3 has
been shown to exhibit propensities for aggregation (Son et al.,
2003), implying its involvement in the formation of seeds that
can be taken up by cells. In summary, a seeded aggregation of
SOD1 proteins including wild-type SOD1 will be a key event to
understand progression/propagation of pathological changes in
SOD1-related fALS and even sALS cases without mutations in
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SOD1, and extracellular SOD1 with aberrant conformations is a
promising target for therapeutics of those devastating diseases.
ACKNOWLEDGMENTS
This work was supported by Grants-in-Aid 24111542 for Sci-
entific Research on Innovative Areas, 25291028 for Scientific
Research (B), and 24657093 for Challenging Exploratory Research
(to Yoshiaki Furukawa) from the Ministry of Education, Culture,
Sports, Science and Technology of Japan.
REFERENCES
Aguzzi, A., and Rajendran, L. (2009). The transcellular spread of cytosolic amyloids,
prions, and prionoids. Neuron 64, 783–790. doi: 10.1016/j.neuron.2009.12.016
Arai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., et al.
(2006). TDP-43 is a component of ubiquitin-positive tau-negative inclusions in
frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem.
Biophys. Res. Commun. 351, 602–611. doi: 10.1016/j.bbrc.2006.10.093
Basso, M., Pozzi, S., Tortarolo, M., Fiordaliso, F., Bisighini, C., Pasetto, L., et al.
(2013). Mutant copper-zinc superoxide dismutase (SOD1) induces protein
secretion pathway alterations and exosome release in astrocytes: implications for
disease spreading and motor neuron pathology in amyotrophic lateral sclerosis.
J. Biol. Chem. 288, 15699–15711. doi: 10.1074/jbc.m112.425066
Bruijn, L. I., Houseweart, M. K., Kato, S., Anderson, K. L., Anderson, S. D., Ohama,
E., et al. (1998). Aggregation and motor neuron toxicity of an ALS-linked SOD1
mutant independent from wild-type SOD1. Science 281, 1851–1854. doi: 10.
1126/science.281.5384.1851
Bruijn, L. I., Miller, T. M., and Cleveland, D. W. (2004). Unraveling the mechanisms
involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 27, 723–
749. doi: 10.1146/annurev.neuro.27.070203.144244
Chang, L. Y., Slot, J. W., Geuze, H. J., and Crapo, J. D. (1988). Molecular immuno-
cytochemistry of the CuZn superoxide dismutase in rat hepatocytes. J. Cell. Biol.
107, 2169–2179. doi: 10.1083/jcb.107.6.2169
Chia, R., Tattum, M. H., Jones, S., Collinge, J., Fisher, E. M., and Jackson, G. S.
(2010). Superoxide dismutase 1 and tgSOD1 mouse spinal cord seed fibrils,
suggesting a propagative cell death mechanism in amyotrophic lateral sclerosis.
PLoS One 5:e10627. doi: 10.1371/journal.pone.0010627
Dobson, C. M. (1999). Protein misfolding, evolution and disease. Trends Biochem.
Sci. 24, 329–332. doi: 10.1016/S0968-0004(99)01445-0
Folz, R. J., and Crapo, J. D. (1994). Extracellular superoxide dismutase (SOD3):
tissue-specific expression, genomic characterization, and computer-assisted
sequence analysis of the human EC SOD gene. Genomics 22, 162–171. doi: 10.
1006/geno.1994.1357
Forman, H. J., and Fridovich, I. (1973). On the stability of bovine superoxide
dismutase. The effects of metals. J. Biol. Chem. 248, 2645–2649.
Furukawa, Y. (2012a). Pathological roles of wild-type Cu,Zn-superoxide dismu-
tase in amyotrophic lateral sclerosis. Neurol. Res. Int. 2012:323261. doi: 10.
1155/2012/323261
Furukawa, Y. (2012b). “Protein aggregates in pathological inclusions of amy-
otrophic lateral sclerosis,” in Amyotrophic Lateral Sclerosis, ed M. H. Maurer
(Rijeka, Croatia: InTech), 335–356.
Furukawa, Y., Kaneko, K., Watanabe, S., Yamanaka, K., and Nukina, N. (2013).
Intracellular seeded aggregation of mutant Cu,Zn-superoxide dismutase asso-
ciated with amyotrophic lateral sclerosis. FEBS Lett. 587, 2500–2505. doi: 10.
1016/j.febslet.2013.06.046
Furukawa, Y., Kaneko, K., Yamanaka, K., and Nukina, N. (2010). Mutation-
dependent polymorphism of Cu,Zn-superoxide dismutase aggregates in the
familial form of amyotrophic lateral sclerosis. J. Biol. Chem. 285, 22221–22231.
doi: 10.1074/jbc.m110.113597
Furukawa, Y., Kaneko, K., Yamanaka, K., O’Halloran, T. V., and Nukina, N. (2008).
Complete loss of post-translational modifications triggers fibrillar aggregation
of SOD1 in familial form of ALS. J. Biol. Chem. 283, 24167–24176. doi: 10.
1074/jbc.m802083200
Furukawa, Y., and O’Halloran, T. V. (2005). Amyotrophic lateral sclerosis mutations
have the greatest destabilizing effect on the apo, reduced form of SOD1, leading
to unfolding and oxidative aggregation. J. Biol. Chem. 280, 17266–17274. doi: 10.
1074/jbc.m500482200
Furukawa, Y., Torres, A. S., and O’Halloran, T. V. (2004). Oxygen-induced matura-
tion of SOD1: a key role for disulfide formation by the copper chaperone CCS.
EMBO J. 23, 2872–2881. doi: 10.1038/sj.emboj.7600276
Gibbs, C. J. Jr., Amyx, H. L., Bacote, A., Masters, C. L., and Gajdusek, D. C. (1980).
Oral transmission of kuru, Creutzfeldt-Jakob disease and scrapie to nonhuman
primates. J. Infect. Dis. 142, 205–208. doi: 10.1093/infdis/142.2.205
Grad, L. I., Guest, W. C., Yanai, A., Pokrishevsky, E., O’Neill, M. A., Gibbs, E., et al.
(2011). Intermolecular transmission of superoxide dismutase 1 misfolding in
living cells. Proc. Natl. Acad. Sci. U S A 108, 16398–16403. doi: 10.1073/pnas.
1102645108
Haidet-Phillips, A. M., Hester, M. E., Miranda, C. J., Meyer, K., Braun, L., Frakes,
A., et al. (2011). Astrocytes from familial and sporadic ALS patients are toxic to
motor neurons. Nat. Biotechnol. 29, 824–828. doi: 10.1038/nbt.1957
Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease:
progress and problems on the road to therapeutics. Science 297, 353–356.
doi: 10.1126/science.1072994
Harper, J. D., and Lansbury, P. T. Jr. (1997). Models of amyloid seeding in
Alzheimer’s disease and scrapie: mechanistic truths and physiological con-
sequences of the time-dependent solubility of amyloid proteins. Annu. Rev.
Biochem. 66, 385–407. doi: 10.1146/annurev.biochem.66.1.385
Hayward, L. J., Rodriguez, J. A., Kim, J. W., Tiwari, A., Goto, J. J., Cabelli, D. E.,
et al. (2002). Decreased metallation and activity in subsets of mutant superoxide
dismutases associated with familial amyotrophic lateral sclerosis. J. Biol. Chem.
277, 15923–15931. doi: 10.1074/jbc.m112087200
Holmes, B. B., and Diamond, M. I. (2012). Amyotrophic lateral sclerosis and organ
donation: is there risk of disease transmission? Ann. Neurol. 72, 832–836. doi: 10.
1002/ana.23684
Horwich, A. L., and Weissman, J. S. (1997). Deadly conformations–protein
misfolding in prion disease. Cell 89, 499–510. doi: 10.1016/s0092-8674(00)
80232-9
Kanouchi, T., Ohkubo, T., and Yokota, T. (2012). Can regional spreading of
amyotrophic lateral sclerosis motor symptoms be explained by prion-like prop-
agation? J. Neurol. Neurosurg. Psychiatry 83, 739–745. doi: 10.1136/jnnp-2011-
301826
Kato, S., Takikawa, M., Nakashima, K., Hirano, A., Cleveland, D. W., Kusaka, H.,
et al. (2000). New consensus research on neuropathological aspects of familial
amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) gene muta-
tions: inclusions containing SOD1 in neurons and astrocytes.Amyotroph. Lateral
Scler. Other Motor Neuron Disord. 1, 163–184. doi: 10.1080/14660820050515160
Kerman, A., Liu, H. N., Croul, S., Bilbao, J., Rogaeva, E., Zinman, L., et al.
(2010). Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive
misfolding of SOD1 is unique to the familial form. Acta Neuropathol. 119, 335–
344. doi: 10.1007/s00401-010-0646-5
Kwiatkowski, T. J. Jr., Bosco, D. A., Leclerc, A. L., Tamrazian, E., Vanderburg, C. R.,
Russ, C., et al. (2009). Mutations in the FUS/TLS gene on chromosome 16
cause familial amyotrophic lateral sclerosis. Science 323, 1205–1208. doi: 10.
1126/science.1166066
McCord, J. M., and Fridovich, I. (1969). Superoxide dismutase. An enzymic
function for erythrocuprein (hemocuprein). J. Biol. Chem. 244, 6049–6055.
Meyer-Luehmann, M., Coomaraswamy, J., Bolmont, T., Kaeser, S., Schaefer, C.,
Kilger, E., et al. (2006). Exogenous induction of cerebral beta-amyloidogenesis
is governed by agent and host. Science 313, 1781–1784. doi: 10.1126/science.
1131864
Mondola, P., Annella, T., Santillo, M., and Santangelo, F. (1996). Evidence for secre-
tion of cytosolic CuZn superoxide dismutase by Hep G2 cells and human fibrob-
lasts. Int. J. Biochem. Cell Biol. 28, 677–681. doi: 10.1016/1357-2725(96)00004-0
Mondola, P., Annella, T., Seru, R., Santangelo, F., Iossa, S., Gioielli, A., et al. (1998).
Secretion and increase of intracellular CuZn superoxide dismutase content in
human neuroblastoma SK-N-BE cells subjected to oxidative stress. Brain Res.
Bull. 45, 517–520. doi: 10.1016/s0361-9230(97)00438-3
Morimoto, R. I. (2008). Proteotoxic stress and inducible chaperone networks
in neurodegenerative disease and aging. Genes Dev. 22, 1427–1438. doi: 10.
1101/gad.1657108
Münch, C., and Bertolotti, A. (2010). Exposure of hydrophobic surfaces initiates
aggregation of diverse ALS-causing superoxide dismutase-1 mutants. J. Mol.
Biol. 399, 512–525. doi: 10.1016/j.jmb.2010.04.019
Münch, C., O’Brien, J., and Bertolotti, A. (2011). Prion-like propagation of mutant
superoxide dismutase-1 misfolding in neuronal cells. Proc. Natl. Acad. Sci. U S A
108, 3548–3553. doi: 10.1073/pnas.1017275108
Frontiers in Cellular Neuroscience www.frontiersin.org March 2014 | Volume 8 | Article 83 | 4
Furukawa and Ogawa Seeded aggregation of SOD1
Nelson, R., Sawaya, M. R., Balbirnie, M., Madsen, A. O., Riekel, C., Grothe, R., et al.
(2005). Structure of the cross-beta spine of amyloid-like fibrils. Nature 435, 773–
778. doi: 10.1038/nature03680
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou,
T. T., et al. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration
and amyotrophic lateral sclerosis. Science 314, 130–133. doi: 10.1126/science.
1134108
Pokrishevsky, E., Grad, L. I., Yousefi, M., Wang, J., Mackenzie, I. R., and Cashman,
N. R. (2012). Aberrant localization of FUS and TDP43 is associated with
misfolding of SOD1 in amyotrophic lateral sclerosis. PLoS One 7:e35050. doi: 10.
1371/journal.pone.0035050
Polymenidou, M., and Cleveland, D. W. (2011). The seeds of neurodegeneration:
prion-like spreading in ALS. Cell 147, 498–508. doi: 10.1016/j.cell.2011.10.011
Prusiner, S. B. (1982). Novel proteinaceous infectious particles cause scrapie.
Science 216, 136–144. doi: 10.1126/science.6801762
Ravits, J. M., and La Spada, A. R. (2009). ALS motor phenotype heterogeneity,
focality, and spread: deconstructing motor neuron degeneration. Neurology 73,
805–811. doi: 10.1212/wnl.0b013e3181b6bbbd
Ridley, R. M., Baker, H. F., Windle, C. P., and Cummings, R. M. (2006). Very long
term studies of the seeding of beta-amyloidosis in primates. J. Neural Transm.
113, 1243–1251. doi: 10.1007/s00702-005-0385-2
Robberecht, W., and Philips, T. (2013). The changing scene of amyotrophic lateral
sclerosis. Nat. Rev. Neurosci. 14, 248–264. doi: 10.1038/nrn3430
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A.,
et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated
with familial amyotrophic lateral sclerosis. Nature 362, 59–62. doi: 10.1038/36
4362c0
Ross, C. A., and Poirier, M. A. (2004). Protein aggregation and neurodegenerative
disease. Nat. Med. 10(Suppl.), S10–S17. doi: 10.1038/nm1066
Son, M., Cloyd, C. D., Rothstein, J. D., Rajendran, B., and Elliott, J. L. (2003).
Aggregate formation in Cu,Zn superoxide dismutase-related proteins. J. Biol.
Chem. 278, 14331–14336. doi: 10.1074/jbc.m211698200
Soto, C. (2003). Unfolding the role of protein misfolding in neurodegenerative
diseases. Nat. Rev. Neurosci. 4, 49–60. doi: 10.1038/nrn1007
Soto, C. (2012). Transmissible proteins: expanding the prion heresy. Cell 149, 968–
977. doi: 10.1016/j.cell.2012.05.007
Tiwari, A., and Hayward, L. J. (2003). Familial amyotrophic lateral sclerosis mutants
of copper/zinc superoxide dismutase are susceptible to disulfide reduction. J.
Biol. Chem. 278, 5984–5992. doi: 10.1074/jbc.m210419200
Toichi, K., Yamanaka, K., and Furukawa, Y. (2013). Disulfide scrambling describes
the oligomer formation of superoxide dismutase (SOD1) proteins in the familial
form of amyotrophic lateral sclerosis. J. Biol. Chem. 288, 4970–4980. doi: 10.
1074/jbc.m112.414235
Treusch, S., Cyr, D. M., and Lindquist, S. (2009). Amyloid deposits: protection
against toxic protein species? Cell Cycle 8, 1668–1674. doi: 10.4161/cc.8.11.8503
Turner, B. J., Atkin, J. D., Farg, M. A., Zang, D. W., Rembach, A., Lopes, E. C.,
et al. (2005). Impaired extracellular secretion of mutant superoxide dismutase
1 associates with neurotoxicity in familial amyotrophic lateral sclerosis. J.
Neurosci. 25, 108–117. doi: 10.1523/jneurosci.4253-04.2005
Turner, B. J., and Talbot, K. (2008). Transgenics, toxicity and therapeutics in rodent
models of mutant SOD1-mediated familial ALS. Prog. Neurobiol. 85, 94–134.
doi: 10.1016/j.pneurobio.2008.01.001
Urushitani, M., Ezzi, S. A., and Julien, J. P. (2007). Therapeutic effects of immu-
nization with mutant superoxide dismutase in mice models of amyotrophic
lateral sclerosis. Proc. Natl. Acad. Sci. U S A 104, 2495–2500. doi: 10.1073/pnas.
0606201104
Urushitani, M., Sik, A., Sakurai, T., Nukina, N., Takahashi, R., and Julien, J. P.
(2006). Chromogranin-mediated secretion of mutant superoxide dismutase
proteins linked to amyotrophic lateral sclerosis. Nat. Neurosci. 9, 108–118.
doi: 10.1038/nn1603
Vance, C., Rogelj, B., Hortobagyi, T., De Vos, K. J., Nishimura, A. L., Sreedharan, J.,
et al. (2009). Mutations in FUS, an RNA processing protein, cause familial amy-
otrophic lateral sclerosis type 6. Science 323, 1208–1211. doi: 10.1126/science.
1165942
Wang, J., Xu, G., Gonzales, V., Coonfield, M., Fromholt, D., Copeland, N. G.,
et al. (2002). Fibrillar inclusions and motor neuron degeneration in transgenic
mice expressing superoxide dismutase 1 with a disrupted copper-binding site.
Neurobiol. Dis. 10, 128–138. doi: 10.1006/nbdi.2002.0498
Wang, Q., Johnson, J. L., Agar, N. Y., and Agar, J. N. (2008). Protein aggregation and
protein instability govern familial amyotrophic lateral sclerosis patient survival.
PLoS Biol. 6:e170. doi: 10.1371/journal.pbio.0060170
Winklhofer, K. F., Tatzelt, J., and Haass, C. (2008). The two faces of protein
misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J.
27, 336–349. doi: 10.1038/sj.emboj.7601930
Zetterström, P., Andersen, P. M., Brännström, T., and Marklund, S. L. (2011).
Misfolded superoxide dismutase-1 in CSF from amyotrophic lateral scle-
rosis patients. J. Neurochem. 117, 91–99. doi: 10.1111/j.1471-4159.2011.
07177.x
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 19 August 2013; accepted: 03 March 2014; published online: 18 March 2014.
Citation: Ogawa M and Furukawa Y (2014) A seeded propagation of Cu, Zn-
superoxide dismutase aggregates in amyotrophic lateral sclerosis. Front. Cell. Neurosci.
8:83. doi: 10.3389/fncel.2014.00083
This article was submitted to the journal Frontiers in Cellular Neuroscience.
Copyright © 2014 Ogawa and Furukawa. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Cellular Neuroscience www.frontiersin.org March 2014 | Volume 8 | Article 83 | 5
